Drugmakers' annual price hikes lower in 2018 than previous years: 3 things to know

After a year filled with immense scrutiny over high drug prices, drug companies still made annual price hikes on many medications, although the increases were smaller than previous years, according to Reuters.

1. Most drugmakers kept price hikes under a self-imposed limit of 10 percent.

"Drug price increases are somewhat more constrained in 2017 and 2018 than they have been previously," Cowen and Co. analyst Eric Schmidt told Reuters.

2. Allergan increased prices for 18 drugs, according to a research note Jeffries released Tuesday. Company spokesman Mark Marmur said Allergan will not increase the prices of these drugs again in 2018. Among the drugs to see price hikes were Restasis, a dry-eye medication, and Linzess, a drug for irritable bowel syndrome, which both saw a 9.5 percent increase.

3. Other drugmakers participating in price increases include Amgen, Teva Pharmaceutical Industries and Horizon Pharma, according to analysts.

4. Amgen raised the price of its best-selling drug Enbrel, used to treat rheumatoid arthritis and psoriasis, by 9.7 percent.

More articles on supply chain:

FDA ends 2017 with 46 new drug approvals – the most in 2 decades
California city could be first in US to use drones to deliver blood
Mold-contaminated antibiotic recalled nationwide: 5 things to know

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.